These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 19838642)

  • 1. Inhibition of both thioredoxin reductase and glutathione reductase may contribute to the anticancer mechanism of TH-302.
    Li S; Zhang J; Li J; Chen D; Matteucci M; Curd J; Duan JX
    Biol Trace Elem Res; 2010 Sep; 136(3):294-301. PubMed ID: 19838642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds.
    Witte AB; Anestål K; Jerremalm E; Ehrsson H; Arnér ES
    Free Radic Biol Med; 2005 Sep; 39(5):696-703. PubMed ID: 16085187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclophosphamide as a potent inhibitor of tumor thioredoxin reductase in vivo.
    Wang X; Zhang J; Xu T
    Toxicol Appl Pharmacol; 2007 Jan; 218(1):88-95. PubMed ID: 17156807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of glutathione synthesis eliminates the adaptive response of ascitic hepatoma 22 cells to nedaplatin that targets thioredoxin reductase.
    Wang Y; Lu H; Wang D; Li S; Sun K; Wan X; Taylor EW; Zhang J
    Toxicol Appl Pharmacol; 2012 Dec; 265(3):342-50. PubMed ID: 22982619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amifostine increases cure rate of cisplatin on ascites hepatoma 22 via selectively protecting renal thioredoxin reductase.
    Zhang J; Wang X; Lu H
    Cancer Lett; 2008 Feb; 260(1-2):127-36. PubMed ID: 18039557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ifosfamide induces acute renal failure via inhibition of the thioredoxin reductase activity.
    Zhang J; Lu H
    Free Radic Biol Med; 2007 Dec; 43(12):1574-83. PubMed ID: 18037123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer.
    Sun JD; Liu Q; Wang J; Ahluwalia D; Ferraro D; Wang Y; Duan JX; Ammons WS; Curd JG; Matteucci MD; Hart CP
    Clin Cancer Res; 2012 Feb; 18(3):758-70. PubMed ID: 22184053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thioredoxin reductase inactivation as a pivotal mechanism of ifosfamide in cancer therapy.
    Wang X; Zhang J; Xu T
    Eur J Pharmacol; 2008 Jan; 579(1-3):66-73. PubMed ID: 18028906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase.
    Gandin V; Fernandes AP; Rigobello MP; Dani B; Sorrentino F; Tisato F; Björnstedt M; Bindoli A; Sturaro A; Rella R; Marzano C
    Biochem Pharmacol; 2010 Jan; 79(2):90-101. PubMed ID: 19665452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity.
    Lu J; Papp LV; Fang J; Rodriguez-Nieto S; Zhivotovsky B; Holmgren A
    Cancer Res; 2006 Apr; 66(8):4410-8. PubMed ID: 16618767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noble metal targeting of thioredoxin reductase--covalent complexes with thioredoxin and thioredoxin-related protein of 14 kDa triggered by cisplatin.
    Prast-Nielsen S; Cebula M; Pader I; Arnér ES
    Free Radic Biol Med; 2010 Dec; 49(11):1765-78. PubMed ID: 20851179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism-based inactivation of thioredoxin reductase from Plasmodium falciparum by Mannich bases. Implication for cytotoxicity.
    Davioud-Charvet E; McLeish MJ; Veine DM; Giegel D; Arscott LD; Andricopulo AD; Becker K; Müller S; Schirmer RH; Williams CH; Kenyon GL
    Biochemistry; 2003 Nov; 42(45):13319-30. PubMed ID: 14609342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benzimidazol-2-ylidene gold(I) complexes are thioredoxin reductase inhibitors with multiple antitumor properties.
    Rubbiani R; Kitanovic I; Alborzinia H; Can S; Kitanovic A; Onambele LA; Stefanopoulou M; Geldmacher Y; Sheldrick WS; Wolber G; Prokop A; Wölfl S; Ott I
    J Med Chem; 2010 Dec; 53(24):8608-18. PubMed ID: 21082862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of thioredoxin reductase by mansonone F analogues: Implications for anticancer activity.
    Liu Z; Huang SL; Li MM; Huang ZS; Lee KS; Gu LQ
    Chem Biol Interact; 2009 Jan; 177(1):48-57. PubMed ID: 18822278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the potential of thioredoxin reductase inhibitors for cancer therapy.
    Urig S; Becker K
    Semin Cancer Biol; 2006 Dec; 16(6):452-65. PubMed ID: 17056271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.
    Lu J; Chew EH; Holmgren A
    Proc Natl Acad Sci U S A; 2007 Jul; 104(30):12288-93. PubMed ID: 17640917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diaryl chalcogenides as selective inhibitors of thioredoxin reductase and potential antitumor agents.
    Engman L; Cotgreave I; Angulo M; Taylor CW; Paine-Murrieta GD; Powis G
    Anticancer Res; 1997; 17(6D):4599-605. PubMed ID: 9494575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular pharmacology of evofosfamide (TH-302): A critical re-evaluation of its bystander effects.
    Hong CR; Dickson BD; Jaiswal JK; Pruijn FB; Hunter FW; Hay MP; Hicks KO; Wilson WR
    Biochem Pharmacol; 2018 Oct; 156():265-280. PubMed ID: 30134191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect.
    Hong CR; Wilson WR; Hicks KO
    Neoplasia; 2019 Feb; 21(2):159-171. PubMed ID: 30591421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine models.
    Liapis V; Zinonos I; Labrinidis A; Hay S; Ponomarev V; Panagopoulos V; Zysk A; DeNichilo M; Ingman W; Atkins GJ; Findlay DM; Zannettino AC; Evdokiou A
    Cancer Med; 2016 Mar; 5(3):534-45. PubMed ID: 26749324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.